Alnylam Signs Licensing Agreement with GeneDesign
News Oct 04, 2007
Alnylam Pharmaceuticals, Inc. and GeneDesign, Inc. announced that Alnylam has granted GeneDesign a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"Obtaining a license to the Kreutzer-Limmer patent estate allows us to augment our RNAi products, thereby strengthening our position in the life sciences marketplace in Asia," said Kazuhiko Yuyama, President of GeneDesign. "This agreement with Alnylam, a leader in the field of RNAi, reinforces our ability to become a leading supplier of innovative reagent products to the pharmaceutical and research community."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019